OS Therapies says Phase 2b Herlystic osteosarcoma trial posts 72.7% three-year overall survival vs 45.8% historical control

Bitget2026/10/06 12:32

OS Therapies released final three-year survival results from its Phase 2b trial of Herlystic in resected pulmonary metastatic osteosarcoma. Patients given Herlystic lived longer than comparable historical controls, supporting the case for earlier access pathways. Work is underway on regulatory submissions in the U.S., U.K., Europe, and Australia, tied to starting a confirmatory Phase 3 study. The program could qualify the company for a U.S. Priority Review Voucher; the most recent sale cited was USD 220 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610060830NEWSFILECNPR____20261006_317620_1) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.